- 1 Dental health of childhood cancer survivors a report from the Swiss Childhood
- 2 Cancer Survivor Study (SCCSS)
- Nigg C¹, Matti C¹, Jörger P^{1,2}, von Bueren AO³, Filippi C⁴, Diesch-Furlanetto T⁵,
- 4 Tomášiková, Z⁶, Kuehni CE^{1,7}, Sommer G¹
- ¹ Institute of Social and Preventive Medicine, University of Bern, Switzerland
- ² Graduate School for Health Sciences, University of Bern, Switzerland
- ³ Department of Paediatrics, Obstetrics and Gynaecology, Division of Paediatric
- 8 Haematology and Oncology, University Hospital of Geneva, Switzerland
- ⁴ Department of Children and Adolescent Dentistry, University Center for Dental Medicine
- 10 Basel (UZB), Basel, Switzerland
- ⁵ Department of Oncology/Haematology, Basel, University Children's Hospital Basel UKBB,
- 12 Basel, Switzerland
- 13 ⁶ Childhood Cancer Switzerland
- ⁷ Division of Pediatric Hematology/Oncology, Inselspital, Bern University Hospital,
- 15 University of Bern, Bern, Switzerland
- 16 Correspondence: Prof. Claudia E. Kuehni, Institute of Social and Preventive Medicine,
- 17 University of Bern, Mittelstrasse 43, 3012 Bern, Switzerland; phone: +41 31 684 35 07,
- 18 e-mail: claudia.kuehni@unibe.ch
- 20 Word count abstract: 249

19

23

- 21 Word count main text: 2,826
- Number of tables: 4; number of figures: 1; number of supporting information files: 1
- 24 Keywords: pediatric oncology, survivorship, late effects, dental care, cohort study, late effects

Abstract

26

49

Dental health of CCS

27 **Background**: Cancer and its treatments can affect dental health of childhood cancer 28 survivors. We aimed to evaluate prevalence of dental problems in survivors, compare them to 29 their siblings, and investigate cancer-related risk factors. 30 **Methods**: As part of the population-based Swiss Childhood Cancer Survivors Study, we sent 31 questionnaires inquiring about dental problems to survivors aged 5-19 years and their 32 siblings. We retrieved cancer-relevant information from the Swiss Childhood Cancer 33 Registry and used logistic regressions to compare dental problems between survivors and 34 siblings and to investigate cancer-related risk factors. 35 **Results**: We included 735 survivors and 144 siblings. Almost half of survivors and siblings 36 reported at least one dental problem. Compared to siblings, survivors had a greater risk for 37 hypo- or microdontia (OR 1.7; 95%CI 0.9-3.2) and enamel hypoplasia (2.2; 0.8-6.0), but similar risk for cavities or cavity-related tooth loss (0.8; 0.6-1.3). Chemotherapy was 38 39 associated with enamel hypoplasia (3.0; 1.2-10.4), cavities or cavity-related tooth loss (1.5; 40 1.0-2.3), and gum problems during (23.0; 9.4-76.2) and after (4.6; 2.0-13.5) treatment. 41 Hematopoietic stem cell transplantation (HSCT) was related to hypo- or microdontia (5.4; 42 2.6-10.7), cavities or cavity-related tooth loss (2.1; 1.2-3.6), and gum problems during 43 treatment (2.0; 1.2-3.6). For hypo- or microdontia and cavities, associations with treatment 44 were driven by patients diagnosed <5 years. 45 **Conclusion:** Childhood cancer patients treated with chemotherapy or HSCT, especially at a 46 young age, were at higher risk for dental problems. Regular dental check-ups guided by 47 healthcare teams and dental hygiene habits can mitigate risks and promote survivor's long-48 term dental health.

It is made available under a CC-BY-NC-ND 4.0 International license .

Introduction

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

Medical advancements allow to cure most children diagnosed with cancer, with 5-year survival rates approaching 90% in Switzerland. Despite those advancements, two thirds of survivors develop somatic late effects of cancer treatments that may include a broad range of health problems. 2-7 Some late effects are already visible shortly after treatment, including dental problems. Early childhood is a crucial phase for crown and root formation, making patients treated with radiation to the head, chemotherapy, or hematopoietic stem cell transplantation (HSCT) particularly susceptible for dental late effects. Radiation to the head and neck area can cause salivary gland hypofunction, resulting in xerostomia and increased caries, 10,11 or damage the tooth bud, disrupting tooth development and leading to structural anomalies, such as enamel hypoplasia, microdontia, or hypodontia. ¹² Chemotherapy, especially alkylating agents, interfere with the cell cycle and the intracellular metabolism, altering odontoblast and ameloblast activity. 11,13 Recipients of HSCT may experience salivary gland hypofunction as a result of conditioning regimes or as an early symptom of chronic graft-versus-host disease. 11,14,15 Two previous meta-analyses including children treated with chemotherapy or a combination of chemotherapy and radiotherapy indicate an increased risk for tooth agenesis and microdontia, enamel hypoplasia, cavities, and gingivitis. 8,16 While most of the studies included used dental examinations, they were restricted to patients receiving specific treatment regimes, or small populations. The few population-based or cohort studies on dental health come from North America and only include adult participants ^{12,17}, who were already in their thirties or forties at time of study. We aimed to evaluate dental health in a population-based study of young childhood cancer survivors (CCS) in Switzerland, a country with different dental hygiene practices and eating habits than North America. ^{18,19} In particular, this study evaluated prevalence of dental problems in pediatric CCS, compared it

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

It is made available under a CC-BY-NC-ND 4.0 International license .

with their siblings, and investigated cancer-related factors contributing to dental problems in pediatric CCS. Methods Study design and study population The Swiss Childhood Cancer Survivor Study (SCCSS) is a population-based study nested in the Swiss Childhood Cancer Registry (ChCR). Detailed methods of the SCCSS are available elsewhere.²⁰ The ChCR includes all children and adolescents diagnosed with leukemias, lymphomas, central nervous system (CNS) tumors, malignant solid tumors, or Langerhans cell histiocytosis prior to age of 20 years in Switzerland since 1976.²¹ As part of the SCCSS, we sent questionnaires to CCS who had survived ≥5 years since their initial diagnosis. Questionnaires are available in German, French, and Italian language. For this study, we included CCS who participated in the SCCSS between 2015 and 2022, were aged between 5 and 19 years at the time of study, and consented to participate. For CCS aged between 5 and 15 years, we asked their parents to fill-in the questionnaire. Siblings of similar age (5-19) years) received the same questionnaire between 2022 and 2024 without cancer-related questions. Ethical approval was granted by the ethics committee of the canton of Bern, Switzerland (KEK-BE: 166/2014 and 2021-01462). Dental health The questionnaire asked CCS and siblings about experiencing hypodontia, microdontia, enamel hypoplasia, cavities, and tooth loss due to cavities and gum disease. It asked CCS, but not siblings, if they experienced gum problems during or after cancer treatment, and if they had problems with health insurance coverage for any dental problems. Participants could report on other dental problems qualitatively in a comment field. For a detailed overview of

Dental health of CCS

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

the questions, please see Supplementary Table 1. For questions in the original language, please contact the authors. Explanatory variables Sociodemographic characteristics. We assessed the following sociodemographic characteristics via questionnaires: Swiss language region, sibling status, parental and participant nationality, and parental education. We categorized the language region into German and French/Italian. We divided CCS' sibling status into yes (≥1 sibling) and no (0 siblings). We used the nationality to define migration background. For migration background and parental education, we applied definitions of the Federal Statistics Office. 22,23 If both parents were born Swiss or if the participant and at least one parent were born Swiss, we defined this as no migration background.²² We considered the highest educational degree obtained by either parent, which we divided into three categories: primary education (compulsory schooling only), secondary education (higher schooling and vocational training), or tertiary education (upper vocational education, university or technical college). ²³ We received date of birth and sex of the CCS from the ChCR and of the siblings from questionnaires. Cancer-related characteristics. We received the following cancer-related characteristics from the ChCR: age at diagnosis, diagnosis according to the International Classification of Childhood Cancer, third edition (ICCC-3)²⁴ and Langerhans Cell Histiocytosis. Treatment information included chemotherapy, radiotherapy, cranial radiation, including radiation to the head, neck or total body irradiation with any dose, HSCT, and relapse (all yes/no).

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

It is made available under a CC-BY-NC-ND 4.0 International license .

Statistical analysis We first weighted siblings using inverse probability weighting to be representative of CCS with regards to sex, age, migration, and language region as described previously. ^{6,25} Secondly, we calculated number and proportion of CCS and their siblings who reported at least one dental problem, as well as for each specific dental problem individually. Third, we used multivariable logistic regression analysis to compare the odds for dental problems between CCS and siblings. For this analysis, we combined hypo- and microdontia into one outcome and cavities and cavity-related tooth loss a second one. We considered adjusting for family clustering via multilevel modeling. Since one-level models yielded similar results, we decided for one-level models due to model parsimony. We computed separate multivariable logistic regression models for each dental problem, deciding a priori to include participant type (CCS/sibling), age at study, and sex as predictors. Fourth, to investigate cancer-related risk factors for each dental problem, we applied multivariable logistic regression analysis using data from CCS. We decided a priori to include chemotherapy, cranial radiation, HSCT, age at diagnosis, age at study, time since diagnosis, and relapse in all models, but dropped age at study due to multicollinearity. Since early childhood is a crucial dentition phase, we ran age-stratified analysis (diagnosis <5 years) for prevalence of dental problems and investigation of cancer-related risk factors. 11 We included all participants responding to at least one dental health question (complete-case analysis). In sensitivity analyses, we imputed missing values using the Multivariate Imputation via Chained Equations (MICE) package ²⁶ to specify an imputation model with the algorithm iteratively imputing multiple possible values for missing values. We ran imputations separately for models comparing CCS and siblings, and for models investigating cancer-related risk factors in CCS. We generated 20 datasets with 20 iterations and pooled results based upon Rubin's rule.²⁷

Dental health of CCS

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

Results In total, of 1597 families with eligible CCS, 1339 were contacted with a questionnaire. Of those, 763 (57%) returned the questionnaire and 735 (55%) responded to at least one question about dental problems. Of 451 families with eligible siblings, 438 were contacted. Of those, 144 responded to at least one question about dental problems (33%). Supplementary Figure 1 shows the study population flow chart with details on reasons for not contacting or exclusion of CCS and siblings. Median age at study was 12.8 years (interquartile range [IQR] 10.2-15.2) for CCS and 13.5 years (IQR 11.1-15.5) for siblings. For CCS, median age at diagnosis was 4.2 years (IQR 2.1-7.2), and median time since diagnosis 8.2 years (IQR 6.9-9.4). Leukemia was the most common cancer diagnosis (41%), followed by CNS tumors (17%) and lymphomas (8%). Eighty percent of CCS had received chemotherapy treatment, 9% cranial radiotherapy, and 9% HSCT (see *Table 1*). Prevalence of dental problems in CCS and comparison with siblings CCS and siblings reported having at least one dental problem with similar frequency, but the type of dental problems differed (Figure 1 and Supplementary Table 2). Eight percent of CCS reported having hypodontia (95% confidence interval (CI) 6-10), 11% microdontia (95% CI 8-13), and 8% (95% CI 6-10) enamel hypoplasia. Cavities were prevalent in 39% of CCS (95% CI 35-43) and tooth loss due to cavities or gum disease in 6% (95% CI 4-7). Thirty-four percent (95% CI 30-37) of CCS reported gum problems during treatment, and 14% (95% CI 11-17) after treatment. When we stratified the analysis by age of diagnosis, we found that compared to cancer patients diagnosed at 5 years or older, cancer patients diagnosed before the age of 5 years had higher prevalence of hypodontia (10% vs. 4%) and microdontia (14% vs. 5%). Gum problems during treatment were more prevalent in cancer patients diagnosed at 5 years or older (39%) compared to those diagnosed before the age of 5 years (30%)

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

It is made available under a CC-BY-NC-ND 4.0 International license .

(Supplementary Table 3). For an overview of prevalence rates in siblings without survey weights and dental problems reported in open questions, see Supplementary Table 4. After controlling for age and sex, we found a trend towards an increased risk for hypo- or microdontia (OR=1.70, 95% CI 0.89-3.24) and enamel hypoplasia (OR=2.23, 95%) CI 0.83-5.96) in CCS compared to siblings. Cavities and tooth loss were similar between CCS and siblings (OR=0.84, 95% CI 0.56-1.28) (see *Table 2*). Of all CCS reporting at least one dental problem (N = 329), 20% reported problems with health care insurance covering associated costs. Insurance problems varied by dental problem (see Supplementary Table 5). Cancer-related risk factors of dental problems in CCS After controlling for age at diagnosis, time since diagnosis, and relapse, chemotherapy treatment was consistently associated with dental problems. This included enamel hypoplasia (OR=3.08, 95% CI 1.22-10.40), cavities or cavity-related tooth loss (OR=1.52, 95% CI 1.01-2.31) as well as gum problems during (OR=22.97, 95% CI 9.37-76.23) and after cancer treatment (OR=4.62, 95% CI 1.98-13.49). We found similar associations between HSCT and dental problems. Specifically, cancer patients who underwent HSCT had an increased risk for hypo- or microdontia (OR = 5.37, 95% CI 2.64-10.69), cavities or cavity-related tooth loss (OR = 2.10, 95%CI 1.24-3.57), and gum problems during treatment (OR = 2.03, 95%CI 1.16-1.16)3.60) compared to CCS without HSCT. Cranial radiation was unrelated to all dental problems (see Table 3). Age stratified analyses showed that associations between cancer-related risk factors and dental problems differed by age group (see Table 4). Cancer patients diagnosed before the age of 5 years had an increased risk for hypo- or microdontia when treated with chemotherapy (OR=5.89, 95% CI 2.08-24.80) or HSCT (OR=2.76, 95% CI 1.34-5.58). They

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

It is made available under a CC-BY-NC-ND 4.0 International license .

were also at higher risk for cavities or cavity-related tooth loss when treated with HSCT (OR=3.25, 95% CI 1.64-6.59). We did not observe those associations in cancer patients diagnosed at the age of 5 years or older. All other treatment-related risk factors were similarly related to dental problems across age diagnosis groups. Sensitivity analysis In imputed data analysis, we included N = 907 study participants (N = 763 CCS, N = 144siblings). Analyses yielded the same conclusions as complete-case analysis; in fact, most associations became stronger and confidence intervals smaller (see Supplementary Table 6 and Supplementary Table 7). **Discussion** This national survey in Switzerland found that CCS were at higher risk for hypo- or microdontia and enamel hypoplasia than their siblings, while cavities and cavity-related tooth loss did not differ between CCS and siblings. Chemotherapy and HSCT were consistently related to dental problems. Cancer patients diagnosed before the age of 5 and treated with chemotherapy or HSCT were particularly susceptible to hypo- or microdontia, as well as cavities or cavity-related tooth loss. The most prevalent dental problem in CCS was cavities. It is difficult to compare prevalence rates for cavities and cavity-related tooth loss to other studies with pediatric CCS since those studies used the composite Decayed, Missing, Filled Teeth (DMFT) score obtained through dental examinations. 8,28 Existing population-based or cohort studies using questionnaires with adult CCS showed that similar to our study, cavities were the most prevalent problem across all dental problems investigated. 12,17 While in our study, prevalence was 8% for hypodontia and 11% for each microdontia and enamel hypoplasia, other studies

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

It is made available under a CC-BY-NC-ND 4.0 International license .

with CCS of similar age indicate higher prevalence for microdontia (16-31%), hypodontia (11-36%), and enamel hypoplasia (12-32%). These differences are likely due to those studies assessing dental problem using dental examinations and clinical methods such as radiographic imaging. When comparing to CCS questionnaire studies in adults, prevalence rates were similar for microdontia (9-14%), hypodontia (8-10%), and enamel hypoplasia (12-17%). 12,17 Higher prevalence of hypo- and microdontia in CCS diagnosed in early childhood was in line with previous findings, ^{29,30} and mirrors young children's susceptibility to dental late effects of cancer treatment due to being in a crucial dentition phase.⁹ In line with our results, studies from clinical examination in pediatric CCS ¹⁶ and in population-based or cohort questionnaire studies with adult CCS ^{12,17} found a higher risk for hypo- or microdontia and enamel hypoplasia in CCS than in controls. Population-based and cohort questionnaire studies with adult CCS also showed that cavity risk is similar in CCS and siblings. 12,17 Similar cavity risk could be due to increased awareness regarding the importance of dental care during cancer treatment, with clinical practitioners taking preventive measures against cavity-related risk factors induced by cancer treatment, such as xerostomia. Another potential explanation is the strong impact of diet and dental hygiene on cavities, ^{32,33} which is likely similar within families (i.e., CCS and the sibling control group), masking the impact of cancer treatment on dental health. Among cancer-related risk factors, chemotherapy was linked to higher risks of enamel hypoplasia, cavities or tooth loss due to cavities, and gum problems both during and after treatment. Previous studies utilizing clinical examinations have reported comparable findings regarding the effects of chemotherapy. 8 HSCT was associated with increased risks of hypoor microdontia, cavities or tooth loss due to cavities, and gum problems during treatment Our results are similar to findings from a review summarizing results of ten studies that CCS who underwent HSCT had an increased risk for micro- and hypodontia, while findings regarding

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

It is made available under a CC-BY-NC-ND 4.0 International license .

the impact of HSCT on cavities are conflicting.³⁴ We found that the risk for dental problems was high when chemotherapy or HSCT was administered at or before the age of 5 years. This demonstrates the profound impact of cancer treatment on dentition in the early years when crown and root formation are occurring. 11 Cranial radiation was unrelated to all dental problems in both overall and age-stratified analysis, which contrasts previous findings. 10,11 There are several potential explanations for this finding. The radiation location in the head or neck-area may not have involved the salivary glands or tooth buds, or the radiation dose could have been too low to cause damage. In Switzerland, proton instead of photon radiotherapy has been increasingly used, which may cause fewer dental problems. 35-37 Further investigations into the underlying reasons are necessary. With one out of five survivors reporting issues with health insurance coverage for dental problems, our study implies that assessing dental health before cancer treatment is crucial to secure insurance coverage for potential post-treatment dental problems in healthcare systems where health insurance covers dental costs only if they are a sequalae of a disease (such as in Switzerland). Healthcare providers are essential to support survivors and their parents in obtaining health insurance coverage and to help CCS monitoring and maintaining dental health. This includes encouraging annual dental check-ups following COG guidelines¹¹ to treat potential conditions and avoid further damage regarding development of the jaw and other teeth resulting from those conditions. Fostering dental hygiene habits such as brushing, flossing, and maintaining a low-sugar diet can further reduce the risk of cavities. Supporting older children and adolescent survivors of childhood cancers in avoiding behaviors like smoking and excessive alcohol consumption can also contribute to better long-term dental health. 38,39 Our population-based, representative study adds evidence to the field of dental late effects by providing results from pediatric CCS between 5-19 years, reducing recall bias,

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

It is made available under a CC-BY-NC-ND 4.0 International license .

providing insights into dental problems of CCS outside North America, and comparing the results to a control group having a similar context as CCS. Previous studies covered only adult CCS or were clinical studies with smaller and selective pediatric populations. We combined patient-reported information with systematically coded clinical information from the ChCR. Our study uses self-reported information about dental problems, which may lead to underestimation of dental late effects. The relatively small number of siblings in the control group may have introduced selection bias. Although we had a large cohort, some dental problems were rare, leading to limited statistical power and bearing the risk that we may have missed associations when comparing the risk for dental problems between CCS and siblings. When we imputed missing data, the associations became stronger and confidence intervals smaller, strengthening confidence in our conclusions. Finally, we did not have detailed treatment information, such as the use of alkylating agents or dental status at the time of treatment, which can modify the effect of cancer-treatment on dental late effects. 11 In conclusion, we found that child and adolescent survivors of childhood cancer have an increased risk for hypodontia, microdontia, and enamel hypoplasia compared to their siblings. Healthcare providers should be aware of the increased risk of dental problems among child and adolescent survivors of childhood cancers, especially if patients were treated with chemotherapy or HSCT before the age of five years.

Conflict of Interest statement

We have no conflict of interests to declare.

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

Acknowledgements We thank all survivors for participating in our study, the study team of the Childhood Cancer Research Group, the data managers of the Swiss Paediatric Oncology Group, and the team of the Swiss Childhood Cancer Registry. **Funding** This study was financially supported by the Swiss Cancer League and Swiss Cancer Research (KLS/KFS-482501-2019, KLS/KFS-5711-01-2022), Kinderkrebshilfe Schweiz (www.kinderkrebshilfe.ch), Kinderkrebs Schweiz (www.kinderkrebs-schweiz.ch) and Stiftung für krebskranke Kinder - Regio Basiliensis (https://www.stiftung-kinderkrebs.ch). Data availability statement The data that support the information of this manuscript were accessed on secured servers of the Institute of Social and Preventive Medicine at the University of Bern. Individual-level, fully anonymized, sensitive data can only be made available for researchers who fulfil the respective legal requirements. Requests of data from the Childhood Cancer Registry must be directed to the Childhood Cancer Registry of Switzerland (https://www.childhoodcancerregistry.ch). Requests of data from the Swiss Childhood Cancer Survivor Study (SCCSS) should be communicated to the study lead Claudia E. Kuehni (claudia.kuehni@unibe.ch).

Dental health of CCS

319	Ref	erences
320	1.	Schindler M, Belle FN, Grotzer MA, Von Der Weid NX, Kuehni CE. Childhood cancer
321		survival in Switzerland (1976–2013): Time ☐ trends and predictors. <i>Int J Cancer</i> .
322		2017;140(1):62-74. doi:10.1002/ijc.30434
323	2.	Bhakta N, Liu Q, Ness KK, et al. The cumulative burden of surviving childhood cancer: an
324		initial report from the St Jude Lifetime Cohort Study (SJLIFE). Lancet. 2017;390(10112):2569-
325		2582. doi:10.1016/s0140-6736(17)31610-0
326	3.	Hammoud RA, Liu Q, Dixon SB, et al. The burden of cardiovascular disease and risk for
327		subsequent major adverse cardiovascular events in survivors of childhood cancer: a
328		prospective, longitudinal analysis from the St Jude Lifetime Cohort Study. Lancet Oncol.
329		2024;25(6):811-822. doi:10.1016/s1470-2045(24)00157-8
330	4.	Christen S, Roser K, Mader L, et al. Incidence and prevalence of musculoskeletal health
331		conditions in survivors of childhood and adolescent cancers: A report from the Swiss childhood
332		cancer survivor study. Cancer Medicine. 2024;13(8):e7204. doi:10.1002/cam4.7204
333	5.	Weiss A, Sommer G, Kasteler R, et al. Long-term auditory complications after childhood
334		cancer: A report from the Swiss Childhood Cancer Survivor Study. Pediatr Blood Cancer.
335		2017;64(2):364-373. doi:10.1002/pbc.26212
336	6.	Kasteler R, Weiss A, Schindler M, et al. Long □ term pulmonary disease among Swiss
337		childhood cancer survivors. <i>Pediatr Blood Cancer</i> . 2018;65(1):e26749. doi:10.1002/pbc.26749
338	7.	Whelan KF, Stratton K, Kawashima T, et al. Ocular late effects in childhood and adolescent
339		cancer survivors: A report from the childhood cancer survivor study. Pediatr Blood Cancer.
340		2010;54(1):103-109. doi:10.1002/pbc.22277
341	8.	Busenhart DM, Erb J, Rigakos G, Eliades T, Papageorgiou SN. Adverse effects of
342		chemotherapy on the teeth and surrounding tissues of children with cancer: A systematic
343		review with meta-analysis. Oral Oncol. 2018;83:64-72.
344		doi:10.1016/j.oraloncology.2018.06.001
345	9.	Smith BH. Standards of human tooth formation and dental age assessment. Wiley-Liss Inc.;
346		1991.

Dental health of CCS 347 10. Milgrom SA, van Luijk P, Pino R, et al. Salivary and Dental Complications in Childhood 348 Cancer Survivors Treated With Radiation Therapy to the Head and Neck: A PENTEC 349 Comprehensive Review. Int J Radiat Oncol Biol Phys. 2024;119(2):467-481. 350 doi:10.1016/j.ijrobp.2021.04.023 351 11. Effinger KE, Migliorati CA, Hudson MM, et al. Oral and dental late effects in survivors of 352 childhood cancer: a Children's Oncology Group report. Support Care Cancer. 353 2014;22(7):2009-2019. doi:10.1007/s00520-014-2260-x 354 12. Kaste SC, Goodman P, Leisenring W, et al. Impact of radiation and chemotherapy on risk of 355 dental abnormalities. Cancer. 2009;115(24):5817-5827. doi:10.1002/cncr.24670 356 13. Kaste SC, Hopkins KP, Jenkins JJI. Abnormal odontogenesis in children treated with radiation 357 and chemotherapy: imaging findings. Am J Roentgenol. 1994;162(6):1407-1411. 358 doi:10.2214/ajr.162.6.8192008 359 14. Imanguli MM, Atkinson JC, Mitchell SA, et al. Salivary Gland Involvement in Chronic Graft-360 Versus-Host Disease: Prevalence, Clinical Significance, and Recommendations for Evaluation. 361 Biol Blood Marrow Transplant. 2010;16(10):1362-1369. doi:10.1016/j.bbmt.2010.03.023 362 15. Dahllöf G, Wondimu B, Barr-Agholme M, Garming-Legert K, Remberger M, Ringdén O. 363 Xerostomia in children and adolescents after stem cell transplantation conditioned with total 364 body irradiation or busulfan. Oral Oncol. 2011;47(9):915-919. 365 doi:10.1016/j.oraloncology.2011.06.509 366 16. Pombo Lopes J, Rodrigues I, Machado V, Botelho J, Bandeira Lopes L. Chemotherapy and 367 Radiotherapy Long-Term Adverse Effects on Oral Health of Childhood Cancer Survivors: A 368 Systematic Review and Meta-Analysis. Cancers. 2023;16(1):110. 369 doi:10.3390/cancers16010110 370 Patni T, Lee C-T, Li Y, et al. Factors for poor oral health in long-term childhood cancer 17. 371 survivors. BMC Oral Health. 2023;23(1):73. doi:10.1186/s12903-023-02762-0 372 18. Maes L, Vereecken C, Vanobbergen J, Honkala S. Tooth brushing and social characteristics of

families in 32 countries. Int Dent J. 2006;56(3):159-167. doi:https://doi.org/10.1111/j.1875-

595X.2006.tb00089.x

373

Dental health of CCS

399

400

375 19. Zaborskis A, Milciuviene S, Narbutaite J, Bendoraitiene E, Kavaliauskiene A. Caries 376 experience and oral health behaviour among 11 -13-year-olds: an ecological study of data from 377 27 European countries, Israel, Canada and USA. Community Dent Health. Jun 2010;27(2):102-378 8. 20. 379 Kuehni CE, Rueegg CS, Michel G, et al. Cohort Profile: The Swiss Childhood Cancer Survivor 380 Study. Int J Epidemiol. 2012;41(6):1553-1564. doi:10.1093/ije/dyr142 381 21. Michel G, von der Weid NX, Zwahlen M, Adam M, Rebholz C, Kuehni CE. The Swiss 382 Childhood Cancer Registry: rationale, organisation and results for the years 2001-2005. Swiss 383 Med Wkly. 2007;137(3536):502-509. 384 22. Statistik Bf. Bevölkerung nach Migrationsstatus [Population and migration status]. Accessed 17 385 April, 2024, https://rb.gy/nf754k 386 Statistik Bf. Bildungssystem [Education system]. Accessed 19 April, 2024, 23. 387 https://www.bfs.admin.ch/bfs/de/home/statistiken/bildung-388 wissenschaft/bildungssystem.assetdetail.223674.html 24. 389 Steliarova | Foucher E, Stiller C, Lacour B, Kaatsch P. International classification of childhood 390 cancer. Cancer. 2005;103(7):1457-1467. 391 25. Gianinazzi ME, Rueegg CS, Von Der Weid NX, Niggli FK, Kuehni CE, Michel G. Mental 392 health-care utilization in survivors of childhood cancer and siblings: the Swiss childhood cancer 393 survivor study. Support Care Cancer. 2014;22(2):339-349. doi:10.1007/s00520-013-1976-3 394 26. Van Buuren S, Groothuis-Oudshoorn K. mice: Multivariate imputation by chained equations in 395 R. Journal of Statistical Software. 2011;45:1-67. 396 27. Carpenter JR, Bartlett JW, Morris TP, Wood AM, Quartagno M, Kenward MG. Multiple 397 imputation and its application. John Wiley & Sons; 2023. 398 28. Defabianis P, Bocca N, Romano F. Prevalence and association of dental anomalies and tooth

decay in Italian childhood cancer survivors. J Clin Pediatr Dent.

2023;doi:10.22514/jocpd.2023.056

- 401 29. Halperson E, Matalon V, Goldstein G, et al. The prevalence of dental developmental anomalies
- 402 among childhood cancer survivors according to types of anticancer treatment. Sci Rep.
- 403 2022;12(1)doi:10.1038/s41598-022-08266-1
- 404 30. Kang C-M, Hahn SM, Kim HS, et al. Clinical Risk Factors Influencing Dental Developmental
- Disturbances in Childhood Cancer Survivors. *Cancer Res Treat*. 2018;50(3):926-935.
- 406 doi:10.4143/crt.2017.296

Dental health of CCS

- 407 31. Quispe RA, Rodrigues ACC, Buaes AMG, Capelozza ALA, Rubira CMF, Santos PSdS. A
- 408 case-control study of dental abnormalities and dental maturity in childhood cancer survivors.
- 409 *Oral Surg Oral Med Oral Radiol.* 2019/11/01/ 2019;128(5):498-507.e3.
- 410 doi:10.1016/j.oooo.2019.07.005
- 411 32. Moynihan P, Petersen PE. Diet, nutrition and the prevention of dental diseases. *Public Health*
- 412 *Nutr.* 2004;7(1a):201-226. doi:10.1079/phn2003589
- 413 33. Kumar S, Tadakamadla J, Johnson NW. Effect of Toothbrushing Frequency on Incidence and
- 414 Increment of Dental Caries: A Systematic Review and Meta-Analysis. *J Dent Res*.
- 415 2016;95(11):1230-1236. doi:10.1177/0022034516655315
- 416 34. Gawade PL, Hudson MM, Kaste SC, et al. A systematic review of dental late effects in
- survivors of childhood cancer. *Pediatr Blood Cancer*. 2014;61(3):407-416.
- 418 doi:10.1002/pbc.24842
- 419 35. Martinsson U, Svärd A-M, Witt Nyström P, et al. Complications after proton radiotherapy in
- 420 children, focusing on severe late complications. A complete Swedish cohort 2008–2019. Acta
- 421 Oncol. 2023;62(10):1348-1356. doi:10.1080/0284186x.2023.2260946
- 422 36. Taylor CL, Price JM. The Tooth Hurts: Dental Health After Radiation Therapy for Head and
- 423 Neck Cancer. Int J Radiat Oncol Biol Phys. 2022;113(2):331-334.
- 424 doi:10.1016/j.ijrobp.2022.01.005
- 425 37. Grant SR, Grosshans DR, Bilton SD, et al. Proton versus conventional radiotherapy for
- 426 pediatric salivary gland tumors: Acute toxicity and dosimetric characteristics. *Radiother Oncol*.
- 427 2015;116(2):309-315. doi:10.1016/j.radonc.2015.07.022

It is made available under a CC-BY-NC-ND 4.0 International license . Dental health of CCS

428 38. Dentistry AAoP. Dental Management of Pediatric Patients Receiving Immunosuppressive 429 Therapy and/or Head and Neck Radiation. The Reference Manual of Pediatric Dentistry. 2023. 430 39. Hong CH, daFonseca M. Considerations in the Pediatric Population with Cancer. Dent Clin 431 North Am. 2008;52(1):155-181. doi:10.1016/j.cden.2007.10.001 432 Legends 433 434 **Abbreviations** 435 CCS = childhood cancer survivors 436 HSCT = hematopoietic stem cell transplantation 437 ChCR = Swiss Childhood Cancer Registry 438 COG = Children's Oncology Group 439 ICCC3 = International Classification of Childhood Cancer, third edition 440 441 **Figures** 442 FIGURE 1 Prevalence of dental problems in childhood cancer survivors and siblings 443 Please note: Only CCS reported gum problems during and after treatment. Percentages are based upon the number of 444 respondents for each dental problem reported in Table 2. For siblings, we report weighted percentages. 445

Dental health of CCS

447

448

449 450 451

452

TABLE 1 Characteristics of childhood cancer survivors and siblings

	Survivors (N = 735)	Siblings (N = 144)			
Socio-demographic characteristics	N	%	N	% ^a	
Age at study (mean, standard error)	13.2 (0.1)		13.5 (0.3)		
(median, IQR)	12.8 [10.2– 15.4]		13.3 [11.1-15.5]		
Age category					
Children (5-15 years)	595	81%	90	77%	
Adolescents (16-19 years)	140	19%	54	23%	
Sex	110				
Girls	341	46%	71	50%	
Boys	394	54%	73	50%	
Migration background	371	0.70	,,,	2070	
No	552	75%	118	76%	
Yes	183	25%	26	24%	
Language	103	2370		2470	
German	516	70%	105	69%	
French	185	25%	33	26%	
French Italian	34	23% 5%	55 6	4%	
Parental education	34	J /0	U	470	
	45	6%	2	1%	
Primary education		33%		30%	
Secondary education	242		44		
Tertiary education	428	58%	98	68%	
Missing	20	3%	0	0%	
Siblings		100/			
No	88	12%			
Yes	630	86%			
Missing	17	2%			
Cancer-related characteristics ^d	N	%			
ICCC3 main group					
Leukemias	299	41%			
Lymphomas	60	8%			
CNS	123	17%			
Neuroblastoma	54	7%			
Retinoblastoma	29	4%			
Renal tumor	48	7%			
Hepatic tumor	6	1%			
Malignant bone tumors	17	2%			
Soft tissue sarcomas	52	7%			
Germ cell tumors	16	2%			
Other	5	1%			
Langerhans cell histiocytosis	26	4%			
Age at diagnosis, mean (SD)	4.9 (3.5)				
median (IQR)	4.2 [2.1 – 7.2]				
Time since diagnosis, mean (SD)	8.3 (1.9)				
median (IQR)	8.2[6.9 - 9.4]				
Year or diagnosis, mean (SD)	2010 (3.2)				
median (IQR)	2010 [2005-2015]	400			
Radiotherapy	137	19%			
Cranial radiotherapy	68	9%			
Chemotherapy	588	80%			
HSCT	69	9%			
Autologous	30	4%			
Allogeneic	39	5%			
Relapse	81	11%			

^a For siblings, the percentages are standardized to survivors based on sex, age at study, migration background, and language. The N is the original value. ^b Calculated based upon weighted t-test for continuous variables and weighted chisquare tests for categorical variables. ^c Not applicable since siblings were standardized based upon these variables to match the CCS. ^d No missing values for cancer-related characteristics.

ICCC3 = International Classification of Childhood Cancer, third edition; HSCT = hematopoietic stem cell transplantation

Dental health of CCS

453 **TABLE 2** Dental problems in childhood cancer survivors compared to siblings in multivariable logistic regressions 454

	I	• •	r microdont N = 875)	ia	Enamel hypoplasia (N = 850)					Cavities or cavity-related tooth loss (N = 868)			
	OR	SE	95%CI	p	OR	SE	95%CI	p	OR	SE	95%CI	p	
CCS (ref. sibling)	1.70	0.56	0.89;3.24	0.106	2.23	1.12	0.83;5.96	0.110	0.84	0.18	0.56;1.28	0.422	
Age at study	0.94	0.03	0.87;1.01	0.079	0.95	0.04	0.88;1.03	0.248	0.98	0.03	0.92;1.04	0.498	
Sex (ref. girls)	0.89	0.24	0.52;1.52	0.662	0.93	0.34	0.45;1.91	0.840	1.05	0.22	0.70;1.57	0.830	

455 456 Please note: We included all participants who provided full data for each of the respective outcomes, resulting in a different N for each model. 457

 $CCS = childhood\ cancer\ survivor$

Dental health of CCS

TABLE 3 Cancer-related risk factors of dental problems in childhood cancer survivors in multivariable logistic regression

462

460

	Hypo- or microdontia (N = 725)						el hypoplasia N = 706)	1	Cavities or cavity-related tooth loss (N = 724)			
	OR	SE	95%CI	p	OR	SE	95%CI	p	OR	SE	95%CI	p
Cranial radiation (ref. no)	0.85	0.46	0.26;2.25	0.762	0.80	0.42	0.25;2.07	0.676	0.88	0.25	0.50;1.51	0.637
Chemotherapy (ref. no)	1.59	0.73	0.70;4.32	0.309	3.08	1.64	1.22;10.40	0.035	1.52	0.32	1.01;2.31	0.049
HSCT (ref. no)	5.37	1.91	2.64;10.69	<0.001	1.74	0.70	0.75;3.70	0.171	2.10	0.56	1.24;3.57	0.006
Age at diagnosis	0.85	0.04	0.76;0.94	0.002	0.92	0.04	0.83;1.00	0.069	1.04	0.02	0.99;1.09	0.094
Time since diagnosis	1.08	0.07	0.94;1.23	0.248	1.02	0.08	0.87;1.17	0.834	1.12	0.05	1.04;1.22	0.005
Relapse (ref. no)	1.11	0.48	0.45;2.49	0.814	2.23	0.86	1.01;4.63	0.038	0.62	0.17	0.35;1.05	0.082

	Gum	•	ns during tre N = 676)	Gum	-	ems after trea N = 637)	tment	
	OR	SE	95%CI	p	OR	SE	95%CI	p
Cranial radiation (ref. no)	1.52	0.45	0.84;2.72	0.163	1.46	0.52	0.70;2.87	0.287
Chemotherapy (ref. no)	22.97	11.97	9.37;76.23	<0.001	4.62	2.21	1.98;13.49	0.001
HSCT (ref. no)	2.03	0.59	1.16;3.60	0.014	1.65	0.57	0.82;3.18	0.147
Age at diagnosis	1.11	0.03	1.06;1.18	<0.001	1.09	0.04	1.02;1.17	0.010
Time since diagnosis	1.01	0.05	0.92;1.12	0.777	1.13	0.07	1.00;1.28	0.041
Relapse (ref. no)	1.04	0.31	0.57;1.85	0.907	1.45	0.52	0.70;2.85	0.301

⁴⁶³ Please note: We included all participants who provided full data for each of the respective outcomes, resulting in a

⁴⁶⁴ different N for each model.

⁴⁶⁵ HSCT = hematopoietic stem cell transplantation

⁴⁶⁶

⁴⁶⁷

⁴⁶⁸

Dental health of CCS

TABLE 4 Age-stratified analysis for cancer-related characteristics and dental problems in childhood cancer survivors

		< :	5 years		=> 5 years						
	OR	SE	95%CI	p	OR	SE	95%CI	р			
Hypo-/microdontia	N = 433				N = 298	3					
Cranial radiation (ref. no)	0.82	0.41	0.28;2.04	0.692	1.77	1.05	0.48;5.24	0.338			
Chemotherapy (ref. no)	5.92	3.62	2.09;24.95	0.004	0.60	0.30	0.23;1.67	0.302			
HSCT (ref. no)	2.88	1.02	1.41;5.74	0.003	1.82	1.23	0.40;6.17	0.378			
Time since diagnosis	1.14	0.07	1.02;1.28	0.020	1.11	0.16	0.83;1.46	0.481			
Enamel hypoplasia	N = 416				N =	290					
Cranial radiation (ref. no)	0.68	0.52	0.11;2.49	0.621	1.44	0.98	0.31;4.88	0.593			
Chemotherapy (ref. no)	2.36	1.46	0.81;10.05	0.168	5.01	5.25	0.97;91.86	0.124			
HSCT (ref. no)	2.32	1.08	0.87;5.55	0.070	1.65	1.14	0.35;5.73	0.466			
Time since diagnosis	1.06	0.08	0.90;1.23	0.441	0.94	0.16	0.66;1.32	0.726			
Cavities or cavity-related tooth loss	N = 428				N =	296					
Cranial radiation (ref. no)	0.40	0.18	0.15;0.94	0.046	1.20	0.44	0.58;2.45	0.609			
Chemotherapy (ref. no)	1.42	0.43	0.79;2.64	0.252	1.73	0.51	0.98;3.15	0.065			
HSCT (ref. no)	2.84	0.97	1.45;5.61	0.002	1.09	0.45	0.47;2.46	0.838			
Time since diagnosis	1.22	0.06	1.11;1.35	< 0.001	0.92	0.07	0.78;1.07	0.276			

Due to low cell count for relapse cases in those aged older than 5 years, we could not control for relapse in this these models.

HSCT = hematopoietic stem cell transplantation

